Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab Plus Albumin Paclitaxel or 5-fluorouracil and Cisplatin Versus 5-fluorouracil and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma: a Prospective, Randomized Controlled Trial Study

NCT06006650 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT06006650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06006650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab Plus Albumin Paclitaxel or 5-fluorouracil and Cisplatin Versus 5-fluorouracil and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma: a Prospective, Randomized Controlled Trial Study
Lead sponsor
Tang-Du Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2022
Completion date
December 31, 2031
Enrollment
114 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, esophageal squamous cell carcinoma, neoadjuvent, pd-1 inhibitor